Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry
SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection. The oversubscribed round was led by Springtide Ventures with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, Recursion CEO and co-founder Chris Gibson, and Recursion co-founder Blake Borgeson.
- SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.
- To achieve this, Leash is producing bespoke, expansive datasets of protein targets binding to chemicals.
- We believe a similar strategy will revolutionize how we approach medicinal chemistry," said Ian Quigley, CEO of Leash Biosciences.
- "Leash's platform stands apart with its combined excellence in machine learning, experimental biology, and medicinal chemistry," said Claire Smith, Lead Investor at Springtide Ventures.